NMTC2
MCID: THY102
MIFTS: 54

Thyroid Cancer, Nonmedullary, 2 (NMTC2)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Thyroid Cancer, Nonmedullary, 2

MalaCards integrated aliases for Thyroid Cancer, Nonmedullary, 2:

Name: Thyroid Cancer, Nonmedullary, 2 57 29 6
Thyroid Carcinoma, Follicular 57 73 20 13
Follicular Thyroid Carcinoma 20 70
Thyroid Cancer, Follicular 20 70
Nmtc2 57 72
Thyroid Carcinoma, Follicular, Somatic 57
Cancer, Thyroid, Nonmedullary, Type 2 39
Thyroid Cancer, Non-Medullary, 2 72
Thyroid Follicular Carcinoma 54
Thyroid Gland Adenocarcinoma 70
Follicular Thyroid Cancer 54
Ftc 20

Characteristics:

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
somatic mutation
autosomal dominant

Miscellaneous:
somatic mutations found in nras


HPO:

31
thyroid cancer, nonmedullary, 2:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:



External Ids:

OMIM® 57 188470
OMIM Phenotypic Series 57 PS188550
MeSH 44 D013964
UMLS 70 C0206682 C1704228 C2931367

Summaries for Thyroid Cancer, Nonmedullary, 2

OMIM® : 57 Nonmedullary thyroid cancer (NMTC) comprises thyroid cancers of follicular cell origin and accounts for more than 95% of all thyroid cancer cases. The remaining cancers originate from parafollicular cells (medullary thyroid cancer, MTC; 155240). NMTC is classified into 4 groups: papillary, follicular, Hurthle cell (607464), and anaplastic. Approximately 5% of NMTC is hereditary, occurring as a minor component of a familial cancer syndrome (e.g., familial adenomatous polyposis, 175100, Carney complex, 160980) or as a primary feature (familial NMTC or FNMTC). Papillary thyroid cancer (PTC) is the most common histologic subtype of FNMTC, accounting for approximately 85% of cases (summary by Vriens et al., 2009). Follicular thyroid cancer (FTC) accounts for approximately 15% of NMTC and is defined by invasive features that result in infiltration of blood vessels and/or full penetration of the tumor capsule, in the absence of the nuclear alterations that characterize papillary carcinoma. FTC is rarely multifocal and usually does not metastasize to the regional lymph nodes but tends to spread via the bloodstream to the lung and bones. An important histologic variant of FTC is the oncocytic (Hurthle cell, oxyphilic) follicular carcinoma composed of eosinophilic cells replete with mitochondria (summary by Bonora et al., 2010). For a general phenotypic description and a discussion of genetic heterogeneity of NMTC, see NMTC1 (188550). (188470) (Updated 20-May-2021)

MalaCards based summary : Thyroid Cancer, Nonmedullary, 2, also known as thyroid carcinoma, follicular, is related to thyroid tumor and differentiated thyroid carcinoma. An important gene associated with Thyroid Cancer, Nonmedullary, 2 is SRGAP1 (SLIT-ROBO Rho GTPase Activating Protein 1), and among its related pathways/superpathways are Focal Adhesion and Aldosterone synthesis and secretion. The drugs Hormones and Sunitinib have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lung and skin, and related phenotypes are follicular thyroid carcinoma and papillary thyroid carcinoma

UniProtKB/Swiss-Prot : 72 Thyroid cancer, non-medullary, 2: A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

Wikipedia : 73 Follicular thyroid cancer accounts for 15% of thyroid cancer and occurs more commonly in women over 50... more...

Related Diseases for Thyroid Cancer, Nonmedullary, 2

Diseases in the Familial Nonmedullary Thyroid Carcinoma family:

Thyroid Cancer, Nonmedullary, 2 Thyroid Cancer, Nonmedullary, 1
Thyroid Cancer, Nonmedullary, 3 Thyroid Cancer, Nonmedullary, 4
Thyroid Cancer, Nonmedullary, 5

Diseases related to Thyroid Cancer, Nonmedullary, 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 296)
# Related Disease Score Top Affiliating Genes
1 thyroid tumor 31.1 PTEN BRAF
2 differentiated thyroid carcinoma 31.0 TSHR TG PPARG PAX8 NRAS HRAS
3 thyroiditis 30.5 TSHR TG CALCA
4 substernal goiter 30.4 TG CALCA
5 malignant struma ovarii 30.3 TG NRAS
6 struma ovarii 30.3 TSHR TG BRAF
7 melanocytic nevus syndrome, congenital 30.2 NRAS LRRC56 HRAS
8 large congenital melanocytic nevus 30.2 NRAS LRRC56 HRAS
9 schimmelpenning-feuerstein-mims syndrome 30.2 NRAS LRRC56 HRAS
10 graves disease 1 30.2 TSHR THRB TG CALCA
11 testicular germ cell tumor 30.2 LRRC56 HRAS BRAF
12 endemic goiter 30.1 TSHR TG CALCA
13 nevus, epidermal 30.0 PTEN NRAS LRRC56 HRAS
14 plummer's disease 30.0 TSHR TG
15 multinodular goiter 30.0 TSHR TG PAX8 HRAS CALCA
16 pseudo-turner syndrome 30.0 NRAS LRRC56 HRAS BRAF
17 graves' disease 29.9 TSHR THRB TG PAX8
18 thyroid carcinoma, familial medullary 29.9 TG CALCA BRAF
19 brain cancer 29.9 PTEN NRAS HRAS BRAF
20 nontoxic goiter 29.9 TSHR TG CALCA
21 congenital hypothyroidism 29.8 TSHR THRB TG PAX8
22 hypothyroidism, congenital, nongoitrous, 2 29.8 TSHR TG PAX8
23 adenoma 29.8 TSHR TG LGALS3 BRAF
24 papillary thyroid microcarcinoma 29.6 TSHR TG CALCA BRAF
25 hyperthyroidism 29.6 TSHR THRB TG CALCA
26 goiter 29.6 TSHR THRB TG PAX8 LGALS3 CALCA
27 renal cell carcinoma, nonpapillary 29.3 PTEN PAX8 NRAS KDR HRAS BRAF
28 thyroid gland medullary carcinoma 29.3 TG PAX8 KDR CALCA
29 glioblastoma 29.1 PTEN PPARG NRAS LRRC56 KDR HRAS
30 nodular goiter 28.9 TSHR TG LGALS3 KDR HRAS CALCA
31 thyroid carcinoma 28.9 TSHR TG PTEN PAX8 LGALS3 CALCA
32 hypothyroidism 28.5 TSHR THRB TG PAX8 LGALS3 CALCA
33 thyroid gland follicular carcinoma 28.5 TSHR THRB TG TFF3 SRGAP1 PTEN
34 hashimoto thyroiditis 28.4 TSHR TG PTEN NRAS LGALS3 HRAS
35 thyroid gland disease 28.3 TSHR THRB TG PPARG PAX8 LGALS3
36 papillary carcinoma 28.1 TSHR TG PPARG PAX8 LGALS3 CALCA
37 thyroid gland anaplastic carcinoma 27.7 TSHR TG PTEN PPARG PAX8 NRAS
38 follicular adenoma 27.6 TSHR TG TFF3 PTEN PPARG PAX8
39 thyroid gland cancer 27.4 TSHR THRB TG PTEN PPARG PAX8
40 familial papillary or follicular thyroid carcinoma 11.3
41 thyroid carcinoma, hurthle cell 11.2
42 tumoral calcinosis, hyperphosphatemic, familial, 1 11.2
43 tumoral calcinosis, hyperphosphatemic, familial, 2 10.9
44 tumoral calcinosis, hyperphosphatemic, familial, 3 10.9
45 familial tumoral calcinosis 10.9
46 48,xyyy 10.4
47 meningeal melanomatosis 10.3 NRAS HRAS
48 immature teratoma of ovary 10.3 TG HRAS
49 malignant anus melanoma 10.3 NRAS HRAS
50 histiocytic sarcoma 10.3 PTEN BRAF

Graphical network of the top 20 diseases related to Thyroid Cancer, Nonmedullary, 2:



Diseases related to Thyroid Cancer, Nonmedullary, 2

Symptoms & Phenotypes for Thyroid Cancer, Nonmedullary, 2

Human phenotypes related to Thyroid Cancer, Nonmedullary, 2:

31
# Description HPO Frequency HPO Source Accession
1 follicular thyroid carcinoma 31 HP:0006731
2 papillary thyroid carcinoma 31 HP:0002895
3 non-medullary thyroid carcinoma 31 HP:0040198

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Neoplasia:
nonmedullary thyroid carcinoma (papillary and follicular)

Clinical features from OMIM®:

188470 (Updated 20-May-2021)

GenomeRNAi Phenotypes related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.89 HRAS
2 Decreased viability GR00055-A-2 9.89 HRAS
3 Decreased viability GR00221-A-1 9.89 HRAS KDR NRAS PPARG
4 Decreased viability GR00221-A-2 9.89 HRAS KDR PPARG
5 Decreased viability GR00221-A-3 9.89 HRAS KDR NRAS PPARG
6 Decreased viability GR00221-A-4 9.89 KDR PPARG
7 Decreased viability GR00249-S 9.89 KDR
8 Decreased viability GR00386-A-1 9.89 PPARG
9 Reduced mammosphere formation GR00396-S 9.17 BRAF HRAS KDR NRAS PAX8 PPARG

MGI Mouse Phenotypes related to Thyroid Cancer, Nonmedullary, 2:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.29 BRAF HRAS KDR LGALS3 NRAS PAX8
2 homeostasis/metabolism MP:0005376 10.29 BRAF HRAS KDR LGALS3 LRRC56 NRAS
3 growth/size/body region MP:0005378 10.24 BRAF HRAS KDR LGALS3 NRAS PAX8
4 cardiovascular system MP:0005385 10.19 BRAF HRAS KDR LGALS3 NRAS PAX8
5 endocrine/exocrine gland MP:0005379 10.16 BRAF HRAS NRAS PAX8 PPARG PTEN
6 immune system MP:0005387 10.16 BRAF KDR LGALS3 NRAS PPARG PTEN
7 digestive/alimentary MP:0005381 10.13 BRAF HRAS LGALS3 NRAS PTEN TFF3
8 nervous system MP:0003631 10.07 BRAF HRAS KDR LGALS3 PAX8 PPARG
9 neoplasm MP:0002006 10.01 BRAF HRAS LGALS3 NRAS PPARG PTEN
10 limbs/digits/tail MP:0005371 9.98 BRAF NRAS PAX8 PTEN TG THRB
11 normal MP:0002873 9.86 BRAF HRAS KDR MINPP1 NRAS PAX8
12 reproductive system MP:0005389 9.81 BRAF LGALS3 LRRC56 PAX8 PPARG PTEN
13 no phenotypic analysis MP:0003012 9.8 HRAS KDR NRAS PAX8 PPARG THRB
14 skeleton MP:0005390 9.7 BRAF HRAS KDR LGALS3 NRAS PAX8
15 vision/eye MP:0005391 9.23 BRAF KDR NRAS PAX8 PPARG PTEN

Drugs & Therapeutics for Thyroid Cancer, Nonmedullary, 2

Drugs for Thyroid Cancer, Nonmedullary, 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 28)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Hormones Phase 3
2
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
3
Iodine Approved, Investigational Phase 2 7553-56-2 807
4
Lithium carbonate Approved Phase 2 554-13-2
5
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
6
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
7
Lenalidomide Approved Phase 2 191732-72-6 216326
8
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
9
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
10
Trametinib Approved Phase 2 871700-17-3 11707110
11
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
12
Cadexomer iodine Experimental Phase 2 94820-09-4
13 Angiogenesis Inhibitors Phase 2
14 Psychotropic Drugs Phase 2
15 Antidepressive Agents Phase 2
16 Anti-Infective Agents Phase 2
17 Immunosuppressive Agents Phase 2
18 Anti-Bacterial Agents Phase 2
19 Immunologic Factors Phase 2
20 Fluorodeoxyglucose F18 Phase 2
21 Radiopharmaceuticals Phase 2
22 Antimetabolites Phase 2
23 Protein Kinase Inhibitors Phase 2
24
Vemurafenib Approved Phase 1 918504-65-1 23252090 42611257
25
Lovastatin Approved, Investigational 75330-75-5 53232
26
Vildagliptin Approved, Investigational 274901-16-5 6918537
27 Dihydromevinolin
28 L 647318

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
2 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
3 The Effects of Lithium Carbonate on Low Dose Radioiodine Ablation in Early Thyroid Cancer Treatment Completed NCT00251316 Phase 2 Lithium Carbonate;Placebo
4 A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma Completed NCT00104871 Phase 2 Bortezomib
5 Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas and Medullary Thyroid Carcinomas Completed NCT00026533 Phase 2 thalidomide
6 Phase II Trial of REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary & Follicular Thyroid Carcinomas Completed NCT00287287 Phase 2 Lenalidomide
7 Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine Completed NCT00085293 Phase 2 Decitabine
8 A Randomized, Double Blind, Placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Vandetanib (ZD6474) in Patients With Locally Advanced or Metastatic Papillary or Follicular Thyroid Carcinoma Failing or Unsuitable for Radioiodine Therapy Active, not recruiting NCT00537095 Phase 2 Vandetanib
9 A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma Active, not recruiting NCT01723202 Phase 2 dabrafenib;trametinib
10 A Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid Cancers Recruiting NCT04462471 Phase 1 Vemurafenib;Copanlisib
11 Multicenter, Prospective, Observational Study of Clinical Outcomes of Thyroid Cancer Recruiting NCT04031339
12 Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients Active, not recruiting NCT02862470
13 Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid Cancer Compared With Usual Initial Management: Multicenter Randomized Prospective Study Not yet recruiting NCT03639662

Search NIH Clinical Center for Thyroid Cancer, Nonmedullary, 2

Genetic Tests for Thyroid Cancer, Nonmedullary, 2

Genetic tests related to Thyroid Cancer, Nonmedullary, 2:

# Genetic test Affiliating Genes
1 Thyroid Cancer, Nonmedullary, 2 29 HRAS MINPP1 NRAS SRGAP1

Anatomical Context for Thyroid Cancer, Nonmedullary, 2

MalaCards organs/tissues related to Thyroid Cancer, Nonmedullary, 2:

40
Thyroid, Lung, Skin, Ovary, Thymus, Pituitary, Lymph Node

Publications for Thyroid Cancer, Nonmedullary, 2

Articles related to Thyroid Cancer, Nonmedullary, 2:

(show top 50) (show all 160)
# Title Authors PMID Year
1
SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility. 6 57
23539728 2013
2
Somatic mutation and germline variants of MINPP1, a phosphatase gene located in proximity to PTEN on 10q23.3, in follicular thyroid carcinomas. 54 6
11297621 2001
3
Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. 6
24006476 2014
4
Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. 6
23392294 2013
5
Keratinocytic epidermal nevi are associated with mosaic RAS mutations. 6
22499344 2012
6
Genetic Predisposition to Familial Nonmedullary Thyroid Cancer: An Update of Molecular Findings and State-of-the-Art Studies. 57
20628519 2010
7
Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. 57
20001717 2009
8
Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. 6
19855393 2009
9
Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis. 6
18633438 2009
10
High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. 6
16187918 2005
11
BRAF mutations in metastatic melanoma: a possible association with clinical outcome. 6
12960123 2003
12
RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. 6
12727991 2003
13
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. 6
12198537 2002
14
Trefoil factor 3 immunohistochemical characterization of follicular thyroid lesions from tissue microarray. 54 61
19528408 2009
15
Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas. 54 61
11967907 2002
16
CCNA1 gene as a potential diagnostic marker in papillary thyroid cancer. 61
33007517 2020
17
A Novel Nanoproteomic Approach for the Identification of Molecular Targets Associated with Thyroid Tumors. 61
33260544 2020
18
ProGRP AS A NOVEL BIOMARKER FOR THE DIFFERENTIAL DIAGNOSIS OF MEDULLARY THYROID CARCINOMA IN PATIENTS WITH THYROID NODULES. 61
32045291 2020
19
Investigation of promoter methylation of FSCN1 gene and FSCN1 protein expression in differentiated thyroid carcinomas. 61
32072403 2020
20
Alterations of regulatory factors and DNA methylation pattern in thyroid cancer. 61
32390600 2020
21
Complete Remission After Single Radioiodine Therapy in Malignant Struma Ovarii With Bone and Lymph Node Metastases. 61
30394923 2019
22
Lenvatinib Administered via Nasogastric Tube in Poorly Differentiated Thyroid Cancer. 61
31641541 2019
23
Diagnostic value of CD56 immunohistochemistry in thyroid lesions. 61
29799356 2018
24
EIF1AX Mutation in a Patient with Hürthle Cell Carcinoma. 61
28965201 2018
25
Special types of thyroid carcinoma. 61
29239042 2018
26
HBME-1 expression in differentiated thyroid carcinoma and its correlation with the ultrasonic manifestation of thyroid. 61
29151906 2017
27
Concurrent Intrathyroidal Thyroid Cancer and Thyroid Cancer in Struma Ovarii: A Case Report and Literature Review. 61
29264493 2017
28
Anaplastic Transformation in Mandibular Metastases of Follicular Variant of Papillary Thyroid Carcinoma: A Case Report and Review of the Literature. 61
27650625 2016
29
Expression and function of CXCL12/CXCR4/CXCR7 in thyroid cancer. 61
27082011 2016
30
Cutaneous metastases on the head and neck from a papillary thyroid carcinoma, follicular variant. 61
26363931 2016
31
A review of the management and prognosis of thyroid carcinoma with tracheal invasion. 61
24972539 2015
32
Incidentally Visualization of the Thymus on Whole-Body Iodine Scintigraphy: Report of 2 Cases and Review of the Latest Insights. 61
26131804 2015
33
Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant. 61
25721865 2015
34
Retrospective analysis of TGF-β 1 expression in patients with thyroidectomy. 61
26406959 2015
35
Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma. 61
23845470 2013
36
Pelvic pain and papillary thyroid carcinoma: case report. 61
23857214 2013
37
Cutaneous metastasis as the presenting sign of papillary thyroid carcinoma. 61
23167299 2013
38
Encapsulated papillary thyroid carcinoma, follicular variant: a misnomer. 61
22360502 2012
39
What if many follicular variant papillary thyroid carcinomas are not malignant? A review of follicular variant papillary thyroid carcinoma and a proposal for a new classification. 61
21940284 2011
40
Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma. 61
21315633 2011
41
Incidental scintigraphic detection of struma ovarii following total thyroidectomy for papillary thyroid cancer. 61
27307906 2011
42
Encapsulated classic and follicular variants of papillary thyroid carcinoma: comparative clinicopathologic study. 61
20497934 2010
43
Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer. 61
20718682 2010
44
Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. 61
20526288 2010
45
RAS mutation-positive follicular variant of papillary thyroid carcinoma arising in a struma ovarii. 61
19898969 2010
46
Evaluation of the PAX8/PPARG translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis. 54
20056739 2010
47
Mixed medullary-papillary carcinoma of the thyroid: a case report. 61
21225751 2010
48
Paired box gene 8-peroxisome proliferator-activated receptor-gamma fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice. 54
19797117 2009
49
Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors. 54
19190121 2009
50
Trefoil factor 3 (TFF3): a promising indicator for diagnosing thyroid follicular carcinoma. 54
18506086 2009

Variations for Thyroid Cancer, Nonmedullary, 2

ClinVar genetic disease variations for Thyroid Cancer, Nonmedullary, 2:

6 (show all 18)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MINPP1 NM_004897.5(MINPP1):c.122C>T (p.Ser41Leu) SNV Pathogenic 5021 rs119486096 GRCh37: 10:89264794-89264794
GRCh38: 10:87505037-87505037
2 MINPP1 NM_004897.5(MINPP1):c.809A>G (p.Gln270Arg) SNV Pathogenic 5022 rs104894171 GRCh37: 10:89268264-89268264
GRCh38: 10:87508507-87508507
3 HRAS , LRRC56 NM_005343.4(HRAS):c.181C>A (p.Gln61Lys) SNV Pathogenic 12601 rs28933406 GRCh37: 11:533875-533875
GRCh38: 11:533875-533875
4 BRAF NM_001374258.1(BRAF):c.1921A>G (p.Lys641Glu) SNV Pathogenic 13966 rs121913364 GRCh37: 7:140453134-140453134
GRCh38: 7:140753334-140753334
5 SRGAP1 NM_020762.4(SRGAP1):c.823G>A (p.Ala275Thr) SNV Pathogenic 208457 rs797044990 GRCh37: 12:64456718-64456718
GRCh38: 12:64062938-64062938
6 HRAS , LRRC56 NM_005343.4(HRAS):c.35G>C (p.Gly12Ala) SNV Pathogenic 12603 rs104894230 GRCh37: 11:534288-534288
GRCh38: 11:534288-534288
7 HRAS , LRRC56 NM_005343.4(HRAS):c.34G>T (p.Gly12Cys) SNV Pathogenic 12613 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
8 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg) SNV Pathogenic 13900 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
9 SRGAP1 NM_020762.4(SRGAP1):c.447A>C (p.Gln149His) SNV Pathogenic 208456 rs781626187 GRCh37: 12:64410750-64410750
GRCh38: 12:64016970-64016970
10 PTEN NM_000314.8(PTEN):c.672del (p.Tyr225fs) Deletion Pathogenic 560358 rs1564566774 GRCh37: 10:89717647-89717647
GRCh38: 10:87957890-87957890
11 HRAS , LRRC56 NM_005343.4(HRAS):c.37G>T (p.Gly13Cys) SNV Pathogenic 12606 rs104894228 GRCh37: 11:534286-534286
GRCh38: 11:534286-534286
12 SRGAP1 NM_020762.4(SRGAP1):c.1849C>T (p.Arg617Cys) SNV risk factor 208458 rs114817817 GRCh37: 12:64502747-64502747
GRCh38: 12:64108967-64108967
13 SRGAP1 NM_020762.4(SRGAP1):c.731_732insAG (p.Leu245fs) Insertion Uncertain significance 931830 GRCh37: 12:64437285-64437286
GRCh38: 12:64043505-64043506
14 SRGAP1 NM_020762.4(SRGAP1):c.182C>T (p.Thr61Met) SNV Uncertain significance 1050742 GRCh37: 12:64377841-64377841
GRCh38: 12:63984061-63984061
15 PTEN NM_000314.8(PTEN):c.235G>A (p.Ala79Thr) SNV Uncertain significance 41682 rs202004587 GRCh37: 10:89690828-89690828
GRCh38: 10:87931071-87931071
16 PTEN NM_000314.8(PTEN):c.882T>G (p.Ser294Arg) SNV Uncertain significance 127693 rs143335584 GRCh37: 10:89720731-89720731
GRCh38: 10:87960974-87960974
17 PTEN NM_000314.8(PTEN):c.892C>G (p.Gln298Glu) SNV Uncertain significance 127695 rs371387815 GRCh37: 10:89720741-89720741
GRCh38: 10:87960984-87960984
18 HRAS , LRRC56 NM_005343.4(HRAS):c.520C>T (p.Pro174Ser) SNV Likely benign 40448 rs397517144 GRCh37: 11:532686-532686
GRCh38: 11:532686-532686

UniProtKB/Swiss-Prot genetic disease variations for Thyroid Cancer, Nonmedullary, 2:

72
# Symbol AA change Variation ID SNP ID
1 HRAS p.Gln61Lys VAR_045979 rs28933406
2 MINPP1 p.Ser41Leu VAR_022836 rs119486096
3 MINPP1 p.Gln270Arg VAR_022837 rs104894171
4 NRAS p.Gln61Arg VAR_006847 rs11554290
5 SRGAP1 p.Gln149His VAR_075879 rs781626187
6 SRGAP1 p.Ala275Thr VAR_075880 rs797044990
7 SRGAP1 p.Arg617Cys VAR_075882 rs114817817
8 SRGAP1 p.His875Arg VAR_075883 rs61754221

Expression for Thyroid Cancer, Nonmedullary, 2

Search GEO for disease gene expression data for Thyroid Cancer, Nonmedullary, 2.

Pathways for Thyroid Cancer, Nonmedullary, 2

Pathways related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.81 PTEN NRAS KDR HRAS BRAF
2
Show member pathways
12.7 TSHR TG PAX8 NRAS HRAS BRAF
3 12.52 PTEN PPARG PAX8 NRAS HRAS BRAF
4
Show member pathways
12.5 PTEN NRAS KDR HRAS
5
Show member pathways
12.42 PTEN PPARG PAX8 NRAS HRAS BRAF
6
Show member pathways
12.41 NRAS HRAS CALCA BRAF
7
Show member pathways
12.33 PTEN NRAS HRAS BRAF
8
Show member pathways
12.3 PTEN NRAS KDR HRAS BRAF
9
Show member pathways
12.26 PTEN NRAS KDR HRAS BRAF
10
Show member pathways
12.25 PTEN NRAS KDR HRAS
11 12.19 NRAS KDR HRAS BRAF
12
Show member pathways
12.18 PPARG NRAS HRAS BRAF
13
Show member pathways
12.08 PTEN NRAS KDR HRAS BRAF
14
Show member pathways
12.06 PPARG NRAS HRAS BRAF
15
Show member pathways
12 NRAS HRAS BRAF
16
Show member pathways
11.96 PTEN NRAS HRAS BRAF
17 11.94 THRB NRAS HRAS
18 11.93 PTEN NRAS HRAS
19 11.91 NRAS HRAS BRAF
20 11.91 PTEN NRAS HRAS
21 11.89 NRAS HRAS BRAF
22
Show member pathways
11.87 NRAS HRAS BRAF
23 11.86 PTEN HRAS BRAF
24 11.71 PTEN NRAS HRAS BRAF
25 11.67 NRAS HRAS BRAF
26 11.66 NRAS HRAS BRAF
27 11.64 PTEN NRAS HRAS
28 11.63 NRAS HRAS BRAF
29 11.61 NRAS HRAS BRAF
30
Show member pathways
11.59 NRAS HRAS BRAF
31 11.55 NRAS HRAS BRAF
32
Show member pathways
11.48 NRAS HRAS BRAF
33
Show member pathways
11.38 NRAS KDR HRAS BRAF
34 11.29 NRAS HRAS BRAF
35 11.2 NRAS HRAS BRAF
36 11.13 PTEN NRAS HRAS
37 11.09 TSHR PAX8 HRAS BRAF
38 10.99 NRAS HRAS
40 10.76 NRAS HRAS
41 10.56 NRAS KDR HRAS BRAF
42 10.36 TSHR TG

GO Terms for Thyroid Cancer, Nonmedullary, 2

Biological processes related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.88 THRB PPARG PAX8 LGALS3 KDR BRAF
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.62 PTEN KDR HRAS BRAF
3 hormone-mediated signaling pathway GO:0009755 9.43 TSHR THRB PPARG
4 regulation of axon regeneration GO:0048679 9.37 PTEN BRAF
5 cellular response to nerve growth factor stimulus GO:1990090 9.33 PTEN CALCA BRAF
6 thyroid-stimulating hormone signaling pathway GO:0038194 8.96 TSHR PAX8
7 thyroid gland development GO:0030878 8.8 TG PAX8 BRAF

Molecular functions related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.16 TSHR THRB TG TFF3 SRGAP1 PTEN
2 protein-containing complex binding GO:0044877 9.55 TSHR NRAS HRAS CALCA BRAF
3 inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity GO:0051717 8.96 PTEN MINPP1
4 thyroid-stimulating hormone receptor activity GO:0004996 8.62 TSHR PAX8

Sources for Thyroid Cancer, Nonmedullary, 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....